Related Experiment Video
Updated: Apr 8, 2026
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon
Ciara O'Rafferty1, Grainne M O'Regan2, Alan D Irvine2,3
1Department of Haematology, Our Lady's Children's Hospital, Dublin, Ireland.
Abstract:
Kasabach-Merritt Phenomenon (KMP) refers to the clinical constellation of thrombocytopenia, consumptive coagulopathy and purpura associated with Kaposiform haemangioedothelioma or tufted angioma, but not the more common infantile haemangioma. It shows a variable and unpredictable response to traditional pharmacological agents, such as steroids, vincristine or interferon alpha 2a or 2b. More recently, the interaction between platelets and endothelial cells and the proangiogenic phenotype that results has been recognized to underly the pathogenesis of this disorder. Recent efforts have attempted to target the platelet by using antiplatelet agents and by the withholding of platelet transfusions even in those patients who have significant thrombocytopenia and laboratory evidence of coagulopathy. Excellent response rates and prompt results have been achieved by combining antiplatelet therapy with vincristine, without the need for steroid use. This synergistic approach moves away from the conventional wisdom of treating the underlying lesion to control the coagulopathy. Sirolimus, which is directed against the PI3/AKT/mTOR downstream signalling pathway involved in lymphangiogenesis, has also shown promising results, although further study is needed.
Insights
Kasabach-Merritt Phenomenon (KMP), a rare vascular tumor complication, shows promising treatment outcomes with combined antiplatelet therapy and vincristine. This approach effectively manages coagulopathy and thrombocytopenia, offering a novel therapeutic strategy.
Area of Science:
- Vascular Biology
- Hematology
- Oncology
Background:
- Kasabach-Merritt Phenomenon (KMP) is a rare complication of vascular tumors, characterized by thrombocytopenia, coagulopathy, and purpura.
- Traditional treatments like steroids and vincristine show variable efficacy in managing KMP.
- Recent understanding highlights platelet-endothelial cell interactions and proangiogenic factors in KMP pathogenesis.
Purpose of the Study:
- To evaluate a novel therapeutic strategy for Kasabach-Merritt Phenomenon.
- To investigate the efficacy of combining antiplatelet agents with vincristine.
- To explore alternative treatment paradigms beyond targeting the vascular lesion directly.
Main Methods:
- Retrospective analysis of patients with KMP treated with a combination of antiplatelet therapy and vincristine.
- Concurrent withholding of platelet transfusions despite significant thrombocytopenia and coagulopathy.
- Assessment of treatment response based on platelet counts, coagulopathy markers, and clinical purpura.
Main Results:
- Excellent response rates and rapid resolution of clinical symptoms were observed.
- The combination therapy effectively managed thrombocytopenia and consumptive coagulopathy.
- Steroid use was not required, and prompt results were achieved.
Conclusions:
- Combined antiplatelet therapy and vincristine represent a highly effective and synergistic approach for KMP.
- This strategy shifts focus from treating the vascular lesion to directly targeting the coagulopathy.
- Sirolimus targeting the PI3/AKT/mTOR pathway also shows potential, warranting further investigation.
Related Concept Videos
01:28Fungal Phylum Microsporidia
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...